AU2004294282B2 - Pharmaceutical combinations - Google Patents

Pharmaceutical combinations Download PDF

Info

Publication number
AU2004294282B2
AU2004294282B2 AU2004294282A AU2004294282A AU2004294282B2 AU 2004294282 B2 AU2004294282 B2 AU 2004294282B2 AU 2004294282 A AU2004294282 A AU 2004294282A AU 2004294282 A AU2004294282 A AU 2004294282A AU 2004294282 B2 AU2004294282 B2 AU 2004294282B2
Authority
AU
Australia
Prior art keywords
rapamycin
subject
methotrexate
hydroxyethyl
arthritis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2004294282A
Other languages
English (en)
Other versions
AU2004294282A1 (en
Inventor
Axel Maibucher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2004294282A1 publication Critical patent/AU2004294282A1/en
Application granted granted Critical
Publication of AU2004294282B2 publication Critical patent/AU2004294282B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2004294282A 2003-12-01 2004-11-30 Pharmaceutical combinations Expired - Fee Related AU2004294282B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0327840.5 2003-12-01
GBGB0327840.5A GB0327840D0 (en) 2003-12-01 2003-12-01 Organic compounds
PCT/EP2004/013587 WO2005053661A2 (en) 2003-12-01 2004-11-30 Pharmaceutical combinations

Publications (2)

Publication Number Publication Date
AU2004294282A1 AU2004294282A1 (en) 2005-06-16
AU2004294282B2 true AU2004294282B2 (en) 2009-05-07

Family

ID=29798110

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004294282A Expired - Fee Related AU2004294282B2 (en) 2003-12-01 2004-11-30 Pharmaceutical combinations

Country Status (11)

Country Link
US (1) US20070117833A1 (https=)
EP (1) EP1819361A2 (https=)
JP (1) JP2007512381A (https=)
KR (1) KR20060122877A (https=)
CN (1) CN1886157A (https=)
AU (1) AU2004294282B2 (https=)
BR (1) BRPI0417146A (https=)
CA (1) CA2546738A1 (https=)
GB (1) GB0327840D0 (https=)
RU (1) RU2006123312A (https=)
WO (1) WO2005053661A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1478648E (pt) 2002-02-01 2014-07-15 Ariad Pharma Inc Compostos contendo fósforo e suas utilizações
WO2006053754A1 (en) * 2004-11-19 2006-05-26 Novartis Ag COMBINATIONS OF ANTI-ATHEROSCLEROTIC PEPTIDES AND AN mTOR INHIBITING AGENT AND THEIR METHODS OF USE
WO2007059106A2 (en) * 2005-11-14 2007-05-24 Ariad Gene Therapeutics, Inc. Administration of mntor inhibitor to treat patients with cancer
EP1880723A1 (en) * 2006-07-14 2008-01-23 Novartis AG Combination of mTOR inhibitor and antifolate compound
WO2007080124A1 (en) * 2006-01-12 2007-07-19 Novartis Ag Combination of mtor inhibitor and antipolate compound
KR20080090493A (ko) * 2006-02-02 2008-10-08 노파르티스 아게 결절성 경화증의 치료
US20090023768A1 (en) * 2006-02-24 2009-01-22 Novartis Ag Rapamycin derivatives for treating neuroblastoma
JP2010509400A (ja) 2006-11-14 2010-03-25 アリアド・ファーマシューティカルズ・インコーポレイテッド 経口処方組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996041807A1 (en) * 1995-06-09 1996-12-27 Novartis Ag Rapamycin derivatives
WO2003027671A2 (en) * 2001-09-25 2003-04-03 Eirx Therapeutics Limited Apoptosis
WO2003057218A1 (en) * 2002-01-10 2003-07-17 Novartis Ag Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof
WO2003064383A2 (en) * 2002-02-01 2003-08-07 Ariad Gene Therapeutics, Inc. Phosphorus-containing compounds & uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
WO2003106622A2 (en) * 2002-05-30 2003-12-24 The Children's Hospital Of Philadelphia Methods for treatment of acute lymphocytic leukemia
TW200509958A (en) * 2003-02-14 2005-03-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996041807A1 (en) * 1995-06-09 1996-12-27 Novartis Ag Rapamycin derivatives
WO2003027671A2 (en) * 2001-09-25 2003-04-03 Eirx Therapeutics Limited Apoptosis
WO2003057218A1 (en) * 2002-01-10 2003-07-17 Novartis Ag Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof
WO2003064383A2 (en) * 2002-02-01 2003-08-07 Ariad Gene Therapeutics, Inc. Phosphorus-containing compounds & uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Boerbooms AM et al. Infections during low-dose methotrexate treatment in rheumatoid arthritis. Semin Arthritis Rheum. 1995 Vol. 24(6) pp 411-21. *
Choi HK et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002 Vol. 359(9313) pp 1173-7. *
Forre O et al. New treatment possibilities in rheumatoid arthritis. Scand J Rheumatol. 2000 Vol. 29(2) pp73-84. *
van Ede et al. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum. 1998 Vol. 27(5) pp 277-92. *

Also Published As

Publication number Publication date
JP2007512381A (ja) 2007-05-17
CA2546738A1 (en) 2005-06-16
WO2005053661A3 (en) 2005-12-29
RU2006123312A (ru) 2008-01-20
KR20060122877A (ko) 2006-11-30
AU2004294282A1 (en) 2005-06-16
WO2005053661A2 (en) 2005-06-16
GB0327840D0 (en) 2003-12-31
US20070117833A1 (en) 2007-05-24
CN1886157A (zh) 2006-12-27
BRPI0417146A (pt) 2007-03-06
EP1819361A2 (en) 2007-08-22

Similar Documents

Publication Publication Date Title
Banerjee et al. JAK–STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects
Johnston et al. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease
Bruyn et al. Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study
US8119649B2 (en) Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia
JP5902141B2 (ja) 脂質キナーゼおよびｍＴＯＲのデュアル阻害剤としてのイミダゾキノリン
JP2020105181A (ja) 同種抗体により駆動される慢性移植片対宿主病を処置及び予防する方法
Furst et al. Effect of aspirin and sulindac on methotrexate clearance
CN101842010A (zh) 使用抗精神病的组合治疗产品来治疗精神分裂症的方法和组合物
AU2011290818B2 (en) Combination anti - cancer therapy
KR20110002848A (ko) 류마티스 관절염 또는 급성 골수성 백혈병을 치료하기 위한 시클로펜타〔ｇ〕퀴나졸린 유도체
MX2008014365A (es) Metodos para tratar enfermedades autoinmunitarias utilizando una molecula de fusion del activador de transmembrana-inmunoglobulina.
AU2004294282B2 (en) Pharmaceutical combinations
AU2021396397A1 (en) Combination therapies for the treatment of cancer
CN109069467A (zh) 肌生成抑制蛋白拮抗剂的用途、含有它们的组合及其用途
US20070225339A1 (en) Compositions and methods for treating rheumatoid arthritis
EP3068491B1 (en) 7-aminocephalosporanic acid derivative as inhibitor of il-15 and il-2 activity
Percy et al. Geropharmacology for the rheumatologist
Sorbera et al. CP-690550
MXPA06006220A (en) Pharmaceutical combinations
EP0505640B2 (en) Improved therapeutic method
WO2019178433A1 (en) Abbv-621 in combination with anti-cancer agents for the treatment of pancreatic cancer
AU2024353689A1 (en) Therapeutic agent for rheumatoid arthritis
WO2025226830A1 (en) Shp2 and egfr inhibitors for the treatment of chordoma
Avdeeva et al. THU0110 The Effect of Subcutaneous (SC) Methotrexate (MTX) and Adalimumab (ADA) on Cytokine Profile in MTX-Naive Patients with Early Rheumatoid Arthritis (RA)
CN117083283A (zh) 用于癌症治疗的联合疗法

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee